Agonist-promoted kappa opioid receptor (KOR) phosphorylation has behavioral endpoint-dependent and sex-specific

Peng Huang1, Chongguang Chen1, Danni Cao1

  • 1Center for Substance Abuse Research (CSAR) & Department of Neural Sciences, Lewis Katz School of Medicine at Temple University, 3500 Broad Street, Philadelphia, PA, 19140, USA.

Neuropharmacology
|November 5, 2021
PubMed

Insights

Agonist-induced kappa opioid receptor (KOR) phosphorylation is crucial for developing tolerance and conditioned place aversion, with significant sex-dependent differences observed in these behaviors. This phosphorylation does not impact acute anti-pruritic or hypo-locomotor effects.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Molecular Biology

Background:

  • Previous in vitro studies identified four key phosphorylation sites on the mouse kappa opioid receptor (mKOR) in response to the selective agonist U50,488H.
  • Understanding the in vivo functional significance of G protein-coupled receptor (GPCR) phosphorylation is essential for elucidating drug mechanisms and behavioral outcomes.

Purpose of the Study:

  • To investigate the in vivo functional role of agonist-induced kappa opioid receptor (KOR) phosphorylation.
  • To determine the sex-specific effects of KOR phosphorylation on behavioral responses to U50,488H.

Main Methods:

  • Generation of a mutant mouse line (K4A) with alanine substitutions at the four identified KOR phosphorylation sites.
  • Assessment of U50,488H-induced KOR phosphorylation in wildtype (WT) and K4A mice using autoradiography for receptor binding.
  • Evaluation of behavioral responses, including scratching, locomotion, tolerance, and conditioned place aversion (CPA), in WT and K4A mice of both sexes.

Main Results:

  • U50,488H induced KOR phosphorylation in WT mice but not in K4A mice, with similar KOR distribution and expression levels observed between genotypes.
  • K4A mice exhibited similar acute anti-pruritic and hypo-locomotor responses to U50,488H as WT mice, indicating phosphorylation is not essential for these acute effects.
  • Tolerance to U50,488H's anti-scratch effects and U50,488H-induced CPA showed significant sex-dependent differences in K4A mice compared to WT mice, highlighting the role of phosphorylation in these specific behaviors.

Conclusions:

  • Agonist-promoted KOR phosphorylation plays a critical role in the development of tolerance and conditioned place aversion (CPA) in a sex-dependent manner.
  • These findings represent the first evidence demonstrating sex differences in the impact of GPCR phosphorylation on GPCR-mediated behaviors.
  • Selective agonist U50,488H's effects on tolerance and CPA are modulated by KOR phosphorylation, with distinct outcomes observed between male and female mice.

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.4K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.1K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
932
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
514
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.6K